echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Layout three product pipelines Zhendong pharmaceutical helps the company's future development with product research and development

    Layout three product pipelines Zhendong pharmaceutical helps the company's future development with product research and development

    • Last Update: 2019-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Zhendong pharmaceutical released the performance forecast for the first three quarters of 2019, and the estimated net profit is about 141 million yuan - 146 million yuan, up 129.64% - 137.76% over the same period of last year The announcement shows that the company's product structure has been continuously optimized, forming an industrial pattern of complementary, anti-tumor and urinary products coordinated development, and the multi-party linkage brand benefits have played a driving role in the company's performance growth In this regard, the relevant head of Zhendong pharmaceutical said that the company is continuously deepening the specialized R & D and layout of three important pipelines, namely "tumor", "urology" and "benefit", so as to enhance the company's core competitiveness and inject strong momentum into the company's performance growth In recent years, Zhendong pharmaceutical has been focusing on the research and development of anti-tumor drugs and market layout Among them, driven by Yanshu compound Sophora flavescens injection, which is the exclusive protected variety of traditional Chinese medicine, the company has gradually expanded the market share of potential varieties such as nitrcard mustard for injection, lentinan for injection, pemetrexed disodium for injection, etc At present, the company is increasing the in-depth research and secondary development of existing anti-tumor products, and making full efforts to promote the project of developing new drug lalotasil liposome At the same time, the company is directly targeting the field of gastric cancer treatment in the research of targeted drug projects In the current situation that there are few clinically available targeted drugs for gastric cancer, the market potential of the drug is huge in the future Thanks to the scientific research status and academic ability established by the compound Sophora flavescens injection Institute, Zhendong pharmaceutical has formed a healthy marketing network and academic network of tumor experts, and the exclusive dosage form of bicalutamide capsule in the urinary pipeline has a strong growth momentum The company is also accelerating the consistency evaluation and in-depth research of bicalutamide capsules, and promoting the development of abitron and other potential follow-up varieties in the urinary pipeline, striving to create the next billion yuan heavyweight product in the urinary pipeline.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.